Skip to content

Human study for investigating the effectiveness and safety of Bacillus coagulans SNZ 1969 on intestinal microflora and defecation.

Human study for investigating the effectiveness and safety of Bacillus coagulans SNZ 1969 on intestinal microflora and defecation.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0002226
Enrollment
80
Registered
2017-02-14
Start date
2017-02-15
Completion date
Unknown
Last updated
2020-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Sponsors

Ewha Womans University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Subject who voluntarily agrees to participate and sign in informed consent form 2) Adults (20 years= Age) 3) Subject who has defecation difficulty - According to Rome III criteria(functional constipation)

Exclusion criteria

Exclusion criteria: 1) Subject who has condition within 1 month as below - Subject who has taken probiotics, prebiotics (dietary fiber, oligosaccharide) over 1 week consistently. - Subject who takes antibiotics over 1 week consistently. 2) Recommended Food Score > 36 3) Subject who has symptoms as below or takes related drugs - irritable bowel syndrome, functional bloating, functional diarrhea - disease could cause of secondary constipation : hypothyroidism, improperly controlled diabetes, dementia, Parkinson's disease, mental illness(depressive disorder, anorexia nervosa), multiple sclerosis, traumatic vertebra injury, organic disturbance of colon, rectum, anus, pelvis (colorectal cancer, lesion of smooth muscle, rectocele, attenuation of fundus pelvis, intrarectal mucosal prolapse, full-thickness rectal prolapse, solitary rectal ulcer syndrome) etc. - severe dysfunction of liver and kidney, alcoholism, cardiovascular disease (including hypertension), immune disease 4) Subject who has hypersensitivity to dietary supplement or ingredients contained in the supplement. 5) Subject who has been in clinical demonstration within 1 months. 6) Pregnant woman or lactating women 7) Subject who judged incongruent by tester through clinical examination center.

Design outcomes

Primary

MeasureTime frame
bowel habit

Secondary

MeasureTime frame
Fecal microbiota

Countries

Korea, Republic of

Contacts

Public ContactMinyoung Park

Ewha Womans University

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026